164 related articles for article (PubMed ID: 37348853)
41. A comprehensive review of childbearing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Papageorgiou D; Manatakis DK; Papakonstantinou K; Kyriazanos ID
Arch Gynecol Obstet; 2020 Oct; 302(4):793-799. PubMed ID: 32653946
[TBL] [Abstract][Full Text] [Related]
42. Learning Curve of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - an Analysis of Critical Perioperative and Surgical Outcomes among 155 Peritoneal Surface Malignancy Patients Treated at a Tertiary Care Cancer Centre.
Saikia J; Deo S; Ray M; Mishra A; Bansal B; Bhoriwal S; Bhatnagar S; Mishra S; Bharti SJ; Kumar V; Kumar M
Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):e305-e311. PubMed ID: 35379523
[TBL] [Abstract][Full Text] [Related]
43. [Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy].
Passot G; Cotte E; Brigand C; Beaujard AC; Isaac S; Gilly FN; Glehen O
J Chir (Paris); 2008; 145(5):447-53. PubMed ID: 19106865
[TBL] [Abstract][Full Text] [Related]
44. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience.
Chua TC; Yan TD; Morris DL
J Surg Oncol; 2009 Feb; 99(2):109-13. PubMed ID: 19016259
[TBL] [Abstract][Full Text] [Related]
45. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases.
Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P
World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066
[TBL] [Abstract][Full Text] [Related]
46. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
Votanopoulos KI; Sugarbaker P; Deraco M; Morris D; Glehen O; Elias D; De Simone M; Robella M; Heyd B; Kusamura S; Baratti D; Chouliaras K; Russell G; Shen P; Levine EA;
Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
[TBL] [Abstract][Full Text] [Related]
47. ASO Author Reflections: Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma treated with CRS-HIPEC.
Chatterjee A; Kusamura S; Baratti D; Guaglio M; Battaglia L; Deraco M
Ann Surg Oncol; 2024 Apr; 31(4):2511-2512. PubMed ID: 38219000
[No Abstract] [Full Text] [Related]
48. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
Chang SC; Fingerhut A; Chen WT
Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
[TBL] [Abstract][Full Text] [Related]
49. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB
Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
[TBL] [Abstract][Full Text] [Related]
50. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
[TBL] [Abstract][Full Text] [Related]
51. Hyperthermic intraperitoneal chemotherapy (HIPEC) as adjuvant and therapeutic options for patients with advanced gastric cancer at high risk of recurrence or established peritoneal metastases: a single-centre experience.
Allievi N; Bianco F; Pisano M; Montori G; Fugazzola P; Coccolini F; Lotti M; Mosconi S; Merelli B; Campanati L; Lucianetti A; Ansaloni L; Magnone S
Updates Surg; 2023 Jan; 75(1):159-167. PubMed ID: 36371549
[TBL] [Abstract][Full Text] [Related]
52. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis.
Hubert J; Thiboutot E; Dubé P; Cloutier AS; Drolet P; Sideris L
Surg Oncol; 2015 Mar; 24(1):41-6. PubMed ID: 25680983
[TBL] [Abstract][Full Text] [Related]
53. Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Rajha A; Piso P; Halmy L; Panczel I; Nedelcut DS; Herold Z; Szasz AM; Acs M
Anticancer Res; 2022 Jul; 42(7):3681-3692. PubMed ID: 35790287
[TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
[TBL] [Abstract][Full Text] [Related]
55. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
56. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience.
Valenzuela CD; Levine EA; Mangieri CW; Gawdi R; Moaven O; Russell G; Lundy ME; Perry KC; Votanopoulos KI; Shen P
Ann Surg Oncol; 2022 Jun; 29(6):3436-3445. PubMed ID: 35286531
[TBL] [Abstract][Full Text] [Related]
57. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
Vaira M; Robella M; Mellano A; Sottile A; De Simone M
Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
[TBL] [Abstract][Full Text] [Related]
58. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Baratti D; Vaira M; Kusamura S; D'Amico S; Balestra MR; Cioppa T; Mingrone E; De Simone M; Deraco M
Eur J Surg Oncol; 2010 Nov; 36(11):1047-53. PubMed ID: 20832234
[TBL] [Abstract][Full Text] [Related]
59. Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre.
Shamavonian R; Cheng E; Karpes JB; Barat S; Ahmadi N; Morris DL
Anticancer Res; 2022 Jun; 42(6):2939-2944. PubMed ID: 35641285
[TBL] [Abstract][Full Text] [Related]
60. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]